Rahman, Proton http://orcid.org/0000-0002-4521-2029
McInnes, Iain B. http://orcid.org/0000-0002-6462-4280
Deodhar, Atul http://orcid.org/0000-0002-2130-1246
Schett, Georg http://orcid.org/0000-0001-8740-9615
Mease, Phillip J. http://orcid.org/0000-0002-6620-0457
Shawi, May http://orcid.org/0000-0001-6005-3938
Cua, Daniel J.
Sherlock, Jonathan P. http://orcid.org/0000-0003-2596-2209
Kollmeier, Alexa P. http://orcid.org/0000-0002-2059-7866
Xu, Xie L.
Sheng, Shihong
Ritchlin, Christopher T. http://orcid.org/0000-0002-2602-1219
McGonagle, Dennis http://orcid.org/0000-0001-7715-8226
Funding for this research was provided by:
Janssen Research and Development
Article History
Received: 4 December 2023
Revised: 21 February 2024
Accepted: 26 February 2024
First Online: 12 March 2024
Declarations
:
: This study was conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practices; the study protocols were approved by an Institutional Review Board or Ethics Committee at each site, and all patients provided written informed consent.
: <b>PR</b> has received consulting fees from AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Merck, Novartis, Pfizer, and UCB; meeting attendance/travel support from Janssen; and research grants from Janssen and Novartis. <b>IBM</b> has received consultant fees from AbbVie, Amgen, Astra Zeneca, Bristol Myers Squibb, Cabaletta, Compugen, Eli Lilly, Gilead, Glaxo Smith Kline, Janssen, Novartis, Pfizer, Roche, Sanofi, and UCB; grant/research support from Amgen, Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Glaxo Smith Kline, Janssen, Novartis, Roche, and UCB; is a shareholder for Causeway Therapeutics, and Evelo Compugen; NHS GGC Board Member; Evelo Board of Directors; and Versus Arthritis Trustee. <b>AD</b> has received consulting fees for participation in Advisory Boards from AbbVie, Amgen, Aurinia, Bristol Myers Squibb, Celgene, Eli Lilly, GlaxoSmithKline, Janssen, MoonLake, Novartis, Pfizer, and UCB; Research Grant funding from AbbVie, Eli Lilly, GlaxoSmithKline, Novartis, Pfizer, and UCB; and Speaker fees from AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. <b>GS</b> has received speaker fees from AbbVie, Bristol Myers Squibb, Eli Lilly, Janssen, and Novartis. <b>PJM</b> has received research grants from AbbVie, Acelyrin, Amgen, Bristol Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer, SUN Pharma, and UCB; consulting fees from AbbVie, Acelyrin, Aclaris, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Immagene, Janssen, Moonlake Pharma, Novartis, Pfizer, SUN Pharma, UCB, Ventyx, and Xinthera; and speaker fees from AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. <b>MS</b>, <b>DJC, JPS, APK, XLX, SS</b> are all employees of Janssen (a subsidiary of Johnson & Johnson) and own Johnson & Johnson stock and/or stock options. <b>CTR</b> has received research support from AbbVie, Amgen, and UCB; consultant fees from AbbVie, Amgen, Eli Lilly, Gilead, Janssen, Novartis, Pfizer, and UCB. <b>DM</b> has received grants/research support: AbbVie, Celgene, Janssen, Merck, Pfizer, Novartis; receipt of honoraria or consultation fees: AbbVie, Celgene, Janssen, Merck, Novartis, Pfizer, UCB; participation in speaker’s bureau: AbbVie, Celgene, Janssen, Merck, Novartis, Pfizer, UCB.